Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727310 | 0.90 | HDAC3 (0.45) | KMT2APPARGPPARAHDAC1HDAC6 | |
| SCHEMBL729135 | 0.86 | KMT2A (0.44) | KMT2APPARGPPARACXCR1HDAC1 | |
| SCHEMBL729075 | 0.83 | HDAC3 (0.44) | KMT2AHDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL728934 | 0.82 | KMT2A (0.41) | KMT2APPARGPPARAHDAC1HDAC6 | |
| SCHEMBL729004 | 0.82 | PRMT1 (0.36) | PPARGHDAC1HDAC6HDAC2HRH3 | |
| SCHEMBL727316 | 0.82 | MEN1 (0.37) | KMT2APPARGHDAC1HDAC6HDAC2 | |
| SCHEMBL729742 | 0.82 | MEN1 (0.37) | KMT2APPARGHDAC1HDAC6HDAC2 | |
| SCHEMBL728860 | 0.81 | PRMT1 (0.39) | MAPTHRH3NPC1RAB9A | |
| SCHEMBL729234 | 0.81 | MEN1 (0.38) | KMT2APPARGHDAC1HDAC6HDAC2 | |
| SCHEMBL727337 | 0.81 | TRPV4 (0.38) | KMT2ACXCR1HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781629-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2015-07-29 | — | — | EP | claimed |
| US-8178688-B2 | Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-05-15 | — | — | US | claimed |
| JP-2011529876-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | claimed |
| EP-2307016-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2011-04-13 | — | — | EP | claimed |
| WO-2010013975-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-04 | — | — | WO | claimed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | claimed |
| US-8178688-B2 | Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | disclosed |
| EP-2307016-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010013975-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | SOST, BPGM, PTH1R | KMT2A 2450/4885PPARG 512/4885PPARA 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.